Fiche publication
Date publication
février 2012
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TAILLANDIER Luc
,
Pr VIGNAUD Jean-Michel
,
Pr GAUCHOTTE Guillaume
,
Dr BATTAGLIA-HSU Shyue-Fang
,
Dr RECH Fabien
Tous les auteurs :
Gauchotte G, Vigouroux C, Rech F, Battaglia-Hsu SF, Soudant M, Pinelli C, Civit T, Taillandier L, Vignaud JM, Bressenot A
Lien Pubmed
Résumé
The 2007 World Health Organization histologic grading of meningiomas is associated with recurrence and clinical outcome. However, distinction of grade I from grade II (atypical) meningiomas can be challenging. In the World Health Organization classification, there are 4 parameters on the basis of which grade II status can be determined: mitotic rate, cytoarchitectural features, brain invasion, and/or histologic subtype. Furthermore, this classification fails to detect grade I recurrent meningiomas, for which other prognostic criteria would be needed. The aim of this study was to evaluate the respective value of several markers involved in cell cycle as effective tools to predict recurrence. This retrospective study was based on a series of 59 meningiomas (grade I: 32 of 59, grade II: 27 of 59, all harboring >/=4 mitoses/1.6 mm), analyzed with the following immunohistochemical markers: MCM6, Ki-67, PHH3, cyclin D1, and p53. We found a significant correlation between histologic grade and mean labeling index for MCM6 (grade I: 21.8% vs. grade II: 65.8%; P
Référence
Am J Surg Pathol. 2012 Feb;36(2):283-91.